Method of treatment of human papillomaviruses related chronic infections

Patent metadata

Field	Value
Publication number	US-11401326-B2
Application number	US-201716303824-A
Country	US
Kind code	B2
Filing date	May 24, 2017
Priority date	May 24, 2016
Publication date	Aug 2, 2022
Grant date	Aug 2, 2022

Abstract

Embodiments of the disclosure relate to the use of an IL-17 pathway inhibitor for treating chronic infections caused by one or more HPVs.

First claim

The invention claimed is:

1. A method of treating a chronic infection caused by one or more human papillomaviruses (HPVs), selected from warts, condylomata, laryngeal papillomatosis and epidermodysplasia verruciformis, the method, comprising administering an effective amount of an antibody that specifically binds interleukin-17A (IL-17A) to a subject in need thereof, said antibody being an inhibitor or an antagonist of IL-17 signalling pathway,
said antibody being selected from the group consisting in Secukinumab and Ixekizumab.

2. The method according to claim 1 , wherein said antibody is administered locally or systemically.

3. The method according to claim 1 , wherein said antibody is Secukinumab administered subcutaneously with a 300 mg dose once a week for five weeks, then every four weeks.

Assignees

• Assist Publique—Hopitaux De Paris
• Univ Paris Diderot—Paris 7
• Assist Publique—Hopitaus De Paris

Inventors

• Descamps Vincent
• Brunet-Possenti Florence

Classifications

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• A61P31/20

  for DNA viruses · CPC title

• C07K16/244 Primary

  Interleukins [IL] · CPC title

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title